Cargando…

Inhibiting the inhibitors: Checkpoints blockade in solid tumors

Detalles Bibliográficos
Autores principales:	Mavilio, Domenico, Lugli, Enrico
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Landes Bioscience 2013
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3825718/ https://www.ncbi.nlm.nih.gov/pubmed/24244910 http://dx.doi.org/10.4161/onci.26535

Ejemplares similares

LIGHTing tumor up for checkpoint blockade
por: Liang, Yong, et al.
Publicado: (2016)

Overcoming immune checkpoint blockade resistance in solid tumors with intermittent ITK inhibition
por: Zhao, Manzhi, et al.
Publicado: (2023)

Corticosteroids and immune checkpoint blockade
por: Min, Le, et al.
Publicado: (2015)

Novel multifunctional antibody approved for the treatment of breast cancer
por: Mavilio, Domenico, et al.
Publicado: (2013)

NK Cell Subset Redistribution during the Course of Viral Infections
por: Lugli, Enrico, et al.
Publicado: (2014)

Heating it up: Oncolytic viruses make tumors ‘hot’ and suitable for checkpoint blockade immunotherapies
por: Gujar, Shashi, et al.
Publicado: (2018)

Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors
por: Miao, Diana, et al.
Publicado: (2018)

Repurposing glucocorticoids as adjuvant reagents for immune checkpoint inhibitors in solid cancers
por: Yu, Yingyan
Publicado: (2021)

The Emerging Role of NK Cells in Immune Checkpoint Blockade
por: Martinez-Perez, Alejandra, et al.
Publicado: (2022)

Re-discovering NK cell allo-reactivity in the therapy of solid tumors
por: Castagna, Luca, et al.
Publicado: (2016)

The Resistance Mechanisms of Checkpoint Inhibitors in Solid Tumors
por: Koustas, Evangelos, et al.
Publicado: (2020)

Identification of biomarkers of immune checkpoint blockade efficacy in recurrent or refractory solid tumor malignancies
por: Yang, Richard K., et al.
Publicado: (2020)

Curing glioblastoma: oncolytic HSV-IL12 and checkpoint blockade
por: Saha, Dipongkor, et al.
Publicado: (2017)

Checkpoint blockade in solid tumors and B-cell malignancies, with special consideration of the role of CD200
por: Gorczynski, Reginald M, et al.
Publicado: (2017)

Combination of radiation therapy, bempegaldesleukin, and checkpoint blockade eradicates advanced solid tumors and metastases in mice
por: Pieper, Alexander A, et al.
Publicado: (2021)

Focused ultrasound-mediated small-molecule delivery to potentiate immune checkpoint blockade in solid tumors
por: Wu, Qiuyu, et al.
Publicado: (2023)

Editorial: Targeting metabolism to activate T cells and enhance the efficacy of checkpoint blockade immunotherapy in solid tumors
por: Xia, Zhijia, et al.
Publicado: (2023)

Proton pump inhibitors and adverse kidney outcomes during immune checkpoint blockade: time to sound the alarm?
por: Tan, Hui Zhuan, et al.
Publicado: (2023)

Cancer Mutational Load: The More the Merrier for Immune Checkpoint Blockade Therapies
Publicado: (2016)

Systemic immunological biomarkers of clinical responses in immune checkpoint blockade therapies
por: Arasanz, Hugo, et al.
Publicado: (2018)

Blockade of checkpoint receptor PVRIG unleashes anti-tumor immunity of NK cells in murine and human solid tumors
por: Li, Yangyang, et al.
Publicado: (2021)

Theory Meets Practice for Immune Checkpoint Blockade in Small-Cell Lung Cancer
por: Riess, Jonathan W., et al.
Publicado: (2016)

Predictive biomarkers for tumor immune checkpoint blockade
por: Tong, Mengting, et al.
Publicado: (2018)

Increasing cure rates of solid tumors by immune checkpoint inhibitors
por: Ma, Weijie, et al.
Publicado: (2023)

Remodeling of the Tumor Microenvironment Through PAK4 Inhibition Sensitizes Tumors to Immune Checkpoint Blockade
por: Abril-Rodriguez, Gabriel, et al.
Publicado: (2022)

Prospects for combining immune checkpoint blockade with PARP inhibition
por: Li, Anping, et al.
Publicado: (2019)

HDAC/IKK inhibition therapies in solid tumors
por: Vancurova, Ivana, et al.
Publicado: (2017)

Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors
por: Peyraud, Florent, et al.
Publicado: (2020)

Hematologic malignancies following immune checkpoint inhibition for solid tumors
por: van Eijs, Mick J. M., et al.
Publicado: (2022)

Immune-related dissociated response as a specific atypical response pattern in solid tumors with immune checkpoint blockade
por: Guan, Yaping, et al.
Publicado: (2022)

Checkpoint kinase 1/2 inhibition potentiates anti-tumoral immune response and sensitizes gliomas to immune checkpoint blockade
por: Dmello, Crismita, et al.
Publicado: (2023)

The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies
por: Petitprez, Florent, et al.
Publicado: (2020)

nab-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors
por: Soliman, Hatem H
Publicado: (2016)

How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors?
por: Denis, Morgane, et al.
Publicado: (2020)

Retreatment with immune checkpoint inhibitors in solid tumors: a systematic review
por: Yang, Kaili, et al.
Publicado: (2020)

Repurposing drugs for solid tumor treatment: focus on immune checkpoint inhibitors
por: Liu, Qingxu, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors in the Pre-operative Setting and Impact on the Primary Renal Tumor
por: Gulati, Shuchi, et al.
Publicado: (2022)

Clinical Potential of Kinase Inhibitors in Combination with Immune Checkpoint Inhibitors for the Treatment of Solid Tumors
por: Ahn, Ryuhjin, et al.
Publicado: (2021)

Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy
por: Hubert, Pascale, et al.
Publicado: (2021)

Nanomaterials-based precision sonodynamic therapy enhancing immune checkpoint blockade: A promising strategy targeting solid tumor
por: Dai, Xinlun, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2i26kc4tnphb57ne7bvfqpsdqa